Metech International Limited 1H2025 Financial Results Analysis

Metech International Limited, listed on the Singapore Catalist Board, has released its unaudited condensed interim financial statements for the six months ended 30 June 2025 (“1H2025”). This article provides a structured analysis of key financial metrics, business developments, and an investor-focused outlook based strictly on the published report.

Key Financial Metrics and YoY/QoQ Comparison

Performance Review & Historical Trends

• Revenue: Surged from S\$41,000 in 1H2024 to S\$3.06 million in 1H2025, driven by the newly launched Health Supplements Business.
• Gross Profit: Increased substantially to S\$338,000, though gross margin fell sharply due to lower margins in the new business line.
• Net Loss: Reduced by 55.9% YoY, but the Group remains loss-making (S\$399,000 loss in 1H2025).
• Net Liability Position: The Group and Company remain in a net liability position, though this improved modestly over the period.
• Working Capital: Still negative at S\$1.80 million, but improved from S\$2.04 million at end-2024.
• Cash Burn: Net cash used in operations increased to S\$2.15 million in 1H2025 (from S\$0.99 million in 1H2024), with closing cash at S\$320,000.
• Dividend: No dividends proposed or paid.

Significant Developments and Events

• Business Diversification: The Group diversified into the Health Supplements Business following shareholder approval in December 2024. The new segment contributed the bulk of revenue in 1H2025, particularly in the PRC market.
• Food Waste Business: Biomass carbon reduction system machines are expected to enter commercial testing in Singapore soon. Negotiations for a joint venture in Taiwan and a collaboration with MLF Ingredients Sdn. Bhd. are ongoing.
• Lab-Grown Diamond Business: Performance continues to disappoint; management is re-evaluating its viability and may curtail further losses.
• Debt and Capitalisation: The Company converted S\$504,000 of employee loans into shares and is proposing to convert a further S\$296,000, reducing liabilities. Additional S\$1.9 million remains available for drawdown under an interest-free loan agreement with the same employee.
• Share Capital: Increased due to loan conversions; as at 30 June 2025, 187,555,655 shares were issued, with further shares proposed pending EGM approval.
• Going Concern: Material uncertainty exists due to recurring losses and negative equity. Management believes going concern is appropriate, citing new business inflows, cost-cutting, further funding options, and support from a key employee/creditor.
• Legal/Receivables: The Company is pursuing a settlement (S\$483,000 plus interest) from a former director, with partial payment received.
• Related Party Transactions: No significant IPTs during the period.
• No Dividend: The Group continues to withhold dividends due to lack of accumulated profits.

Events That Could Affect Future Performance

• Regulatory Approvals: Success in obtaining sales and health supplement licenses in the PRC is key to further revenue growth in the Health Supplements Business.
• Strategic Collaborations: Two memoranda of understanding—one with MLF Ingredients and another with Burpple 2021 Pte. Ltd.—could drive new revenue streams if definitive agreements are reached.
• Cash Flow and Funding: The Group’s ability to secure further funding (notably via loans from a key employee) is crucial to support ongoing operations and new business ventures.

Chairman’s Statement

No explicit Chairman’s Statement was included in the interim report. The report’s narrative tone is cautiously optimistic, emphasizing opportunities in new business lines and collaborations, but clearly acknowledges the Group’s continued losses, negative equity, and dependence on new capital and successful regulatory approvals for viability.

Conclusion & Investment Recommendation

Assessment: Metech International’s financial performance in 1H2025 shows a dramatic increase in revenue and a reduction in losses, primarily due to its new Health Supplements Business. However, profitability remains elusive, cash burn is high, and the Group continues to operate with negative equity and working capital. The viability of its turnaround depends heavily on successful execution of its new business initiatives, securing regulatory approvals, and access to further funding.

• If You Are Currently Holding the Stock: Consider maintaining a cautious stance. The Group has made positive strides in diversifying revenue, but uncertainties around cash flow, funding, and execution risk remain high. Monitor upcoming regulatory approvals, further debt-to-equity conversions, and progress with strategic partners closely. Be prepared to act if liquidity or business execution falters.
• If You Are Not Holding the Stock: Wait for further evidence of sustained profitability, improved cash flow, and successful execution of new business strategies before considering entry. The stock remains high risk due to negative equity and reliance on external funding.

Disclaimer: This article is for informational purposes only, based exclusively on the attached financial report. It does not constitute investment advice. Please consult your own professional adviser before making any investment decisions.

View Metech Intl Historical chart here